Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 28, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 525,000 ordinary shares.
- Purchase Price: 1,229.82 pence per share.
- Treasury Shares Held: 500,694,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,524,652,108 shares (excluding Treasury shares).
Material Changes
The primary material change is the increase in the company's Treasury share holdings following the November 28, 2007 transaction. The total number of shares held in Treasury now represents 9.06% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,524,652,108) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (500,694,158) and its impact on the 9.06% voting rights representation.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.